<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095441</url>
  </required_header>
  <id_info>
    <org_study_id>MVR-C5252-001</org_study_id>
    <nct_id>NCT05095441</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma</brief_title>
  <official_title>A Phase 1 Open-Label Study of Genetically Engineered Oncolytic HSV-1 (C5252) Expressing IL-12 and Anti-PD-1 Antibody in Patients With Recurrent or Progressive Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmVira Pharma Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmVira Pharma Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine&#xD;
      the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with&#xD;
      recurrent or progressive glioblastoma (GBM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine&#xD;
      the safety and tolerability of a single IT injection of C5252 in patients with recurrent or&#xD;
      progressive GBM. The Part 1 portion of the study is a 3+3 design to evaluate escalating doses&#xD;
      of C5252. Total enrollment will depend on the toxicities and/or activity observed, with&#xD;
      approximately 36 evaluable participants enrolled. Once the recommended dose (RD) is&#xD;
      identified from Part 1, Part 2 Dose Expansion will enroll up to 15 additional participants to&#xD;
      further assess the safety, tolerability, and preliminary efficacy of a single IT injection of&#xD;
      C5252 monotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of C5252</measure>
    <time_frame>Up to 28 days from C5252 injection</time_frame>
    <description>Number of participants in dose escalating cohorts with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize Dose Limiting Toxicities</measure>
    <time_frame>Up to 28 days from C5252 injection</time_frame>
    <description>Incidence of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify the maximum tolerated dose (MTD) and/or the RD of C5252</measure>
    <time_frame>Up to 28 days from C5252 injection</time_frame>
    <description>Incidence of DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PK of C5252</measure>
    <time_frame>Up to 2 years from C5252 injection</time_frame>
    <description>Measure anti-PD-1 antibody concentration in blood using Anti-PD-1 antibody ELISA test and IL-12 concentration in blood using IL-12p70 ELISA test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the viral shedding of C5252</measure>
    <time_frame>Up to 2 years from C5252 injection</time_frame>
    <description>Measure viral shedding of C5252 after intratumoral injection in saliva, nasopharyngeal mucus, and urine using qPCR (quantitative polymerase chain reaction) test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 2 years from C5252 injection</time_frame>
    <description>ORR is defined as the proportion of participants who have had a partial response (PR), or complete response (CR) to intervention, based on Investigator Assessment for Neuro-oncology (RANO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years from C5252 injection</time_frame>
    <description>PFS is defined as the time from Day 1 to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first per RANO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years from C5252 injection</time_frame>
    <description>OS is defined as the time from enrollment to death from any cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate blood cytokines</measure>
    <time_frame>Up to 28 days from C5252 injection</time_frame>
    <description>Measure blood cytokines using MSD V-Plex Electrochemiluminescence Immunoassay test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate lymphocyte profiling</measure>
    <time_frame>Up to 28 days from C5252 injection</time_frame>
    <description>Conduct lymphocyte profiling using PBMC Flow cytometry test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Glioblastoma</condition>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Glioblastoma Multiforme of Brain</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C5252 single agent dose escalation in participants with glioblastoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recommended dose of C5252 as determined in Part 1 Dose Escalation in participants with glioblastoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C5252</intervention_name>
    <description>A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.</description>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated approved informed consent form (ICF) before any protocol-directed&#xD;
             screening procedures are performed.&#xD;
&#xD;
          2. Participants must have histopathologically confirmed recurrent supratentorial&#xD;
             glioblastoma.&#xD;
&#xD;
          3. Participants must have progressed after at least 1 line but no more than 2 lines of&#xD;
             therapy.&#xD;
&#xD;
          4. Evidence of progression by RANO criteria based on MRI scan.&#xD;
&#xD;
          5. Residual lesion must be ≥ 1.0 cm and &lt; 5.5 cm contrast-enhancing in diameter as&#xD;
             determined by MRI.&#xD;
&#xD;
          6. Age ≥ 18 years.&#xD;
&#xD;
          7. Karnofsky Performance Score (KPS) ≥ 70.&#xD;
&#xD;
          8. Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          9. Participants must have normal organ and marrow function.&#xD;
&#xD;
         10. Participants must commit to the use of a reliable method of birth control.&#xD;
&#xD;
         11. Resolution of all AEs due to previous therapies to ≤ Grade 1 or baseline.&#xD;
&#xD;
         12. Capable of understanding and complying with protocol requirements.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Inability to undergo MRI examination for any reason.&#xD;
&#xD;
          2. A contrast-enhancing brain tumor that does not meet protocol criteria.&#xD;
&#xD;
          3. Prior history of encephalitis, multiple sclerosis, or other CNS infection.&#xD;
&#xD;
          4. Clinical diagnosis of Li-Fraumeni Syndrome or with a known germ line deficit in the&#xD;
             retinoblastoma gene or its related pathways.&#xD;
&#xD;
          5. Required steroid increase within 2 weeks prior to date of C5252 administration.&#xD;
&#xD;
          6. Systemic therapy with immunosuppressive agents within 28 days prior to date of C5252&#xD;
             administration.&#xD;
&#xD;
          7. Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or any other medical condition that precludes surgery. Also, psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements.&#xD;
&#xD;
          8. Bleeding diathesis, or requirement for anticoagulants, or antiplatelet agents,&#xD;
             including NSAIDs that cannot be stopped for surgery or biopsy.&#xD;
&#xD;
          9. Current diagnosis of other cancer except in situ cervical cancer, basal or squamous&#xD;
             cell carcinoma of the skin.&#xD;
&#xD;
         10. Requires continued concurrent therapy with any drug active against HSV (acyclovir,&#xD;
             valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir).&#xD;
&#xD;
         11. Pregnant or lactating.&#xD;
&#xD;
         12. Prior organ transplantation.&#xD;
&#xD;
         13. Active hepatitis B virus, hepatitis C virus, or a positive serological test at&#xD;
             Screening.&#xD;
&#xD;
         14. Active oral herpes lesion at Screening.&#xD;
&#xD;
         15. Congestive heart failure (&gt; New York Heart Association Class II), active coronary&#xD;
             artery disease, unevaluated new onset angina within 3 months or unstable angina&#xD;
             (angina symptoms at rest), or clinically significant cardiac arrhythmias.&#xD;
&#xD;
         16. History of allergic reactions attributed to compounds of similar biological&#xD;
             composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody.&#xD;
&#xD;
         17. Active infection with SARS-CoV-2 virus.&#xD;
&#xD;
         18. Other systemic conditions or organ abnormalities that, in the opinion of the&#xD;
             Investigator, may interfere with the conduct and/or interpretation of the current&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ImmVira Pharma Co., LTD</last_name>
    <phone>17817185121</phone>
    <email>MVRC5252001@immviragroup.com</email>
  </overall_contact>
  <link>
    <url>http://www.immvira-theravir.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

